Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET)

被引：5
|
作者：
D'Arcangelo, M. [1 ]
Tassinari, D. [2 ]
De Marinis, F. [3 ]
Delmonte, A. [4 ]
Galetta, D. [5 ]
Cecere, F. [6 ]
Pilotto, S. [7 ]
Zanelli, F. [8 ]
Bonanno, L. [9 ]
Landi, L. [1 ]
D'Inca, F. [10 ]
Cappuzzo, F. [1 ]
机构：
[1] Azienda Usl Romagna, Oncol & Hematol, Ravenna, Italy
[2] Ausl Romagna, Rimini, Italy
[3] Ist Europeo Oncol Ircss, Milan, Italy
[4] Ist Sci Romagnolo Studio & Cura Tumori Irst, Meldola, Italy
[5] Clin Canc Ctr Giovanni Paolo Ii, Thorac Med Oncol Unit, Bari, Italy
[6] Ist Nazl Tumori Regina Elena, Rome, Italy
[7] Aou Integrata Verona, Verona, Italy
[8] Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
[9] Ist Oncol Veneto, Padua, Italy
[10] Fdn Ric Traslaz, Rome, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; MET; cabozantinib;
D O I：
10.1016/j.jtho.2019.08.1359
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-15
引用
收藏
页码：S644 / S644
页数：1
相关论文
共 50 条
  • [21] Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer
    Kaira, K
    Takise, A
    Minato, K
    Iwasaki, Y
    Ishihara, S
    Takei, Y
    Tsuchiya, S
    Saito, R
    Sato, K
    Mori, M
    ANTI-CANCER DRUGS, 2005, 16 (04) : 455 - 460
  • [22] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Nukiwa, Toshihiro
    Mori, Kiyoshi
    Tsuboi, Masahiro
    Horai, Takeshi
    Masuda, Noriyuki
    Eguchi, Kenji
    Mitsudomi, Tetsuya
    Yokota, Soichiro
    Segawa, Yoshihiko
    Ichinose, Yukito
    Fukuoka, Masahiro
    Saijo, Nagahiro
    ANTICANCER RESEARCH, 2010, 30 (02) : 557 - 563
  • [23] A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer
    Clarke, SJ
    Boyer, MJ
    Millward, M
    Underhill, C
    Moylan, E
    Yip, D
    White, S
    Childs, A
    Beale, P
    Latz, J
    Suri, A
    Iglesias, JL
    LUNG CANCER, 2005, 49 (03) : 401 - 412
  • [24] A pharmacokinetic and phase II study of gallium nitrate in patients with non-small cell lung cancer
    Webster, LK
    Olver, IN
    Stokes, KH
    Sephton, RG
    Hillcoat, BL
    Bishop, JF
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (01) : 55 - 58
  • [25] Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer
    Ichiki, M
    Rikimaru, T
    Gohara, R
    Koga, T
    Kawayama, T
    Matunami, M
    Oshita, Y
    Kamimura, T
    Aizawa, H
    ONCOLOGY, 2003, 64 (04) : 306 - 311
  • [26] PHASE-II STUDY OF MITOXANTRONE IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER
    SUGA, J
    SAIJO, N
    SHINKAI, T
    EGUCHI, K
    SASAKI, Y
    SAKURAI, M
    SANO, T
    TAMURA, T
    HOSHI, A
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1986, 16 (02) : 147 - 151
  • [27] Phase II study of liarozole in advanced non-small cell lung cancer
    O'Byrne, KJ
    Han, C
    Mitchell, K
    Lane, D
    Carmichael, J
    Harris, AL
    Talbot, DC
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (09) : 1463 - 1466
  • [28] Phase II study of mitonafide in non-small cell lung cancer (NSCLC)
    Casado, A
    Rosell, R
    GarciaGomez, R
    DiazRubio, E
    PerezManga, G
    Font, A
    Benavides, A
    Martin, M
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (04) : 415 - 417
  • [29] Phase II study of dasatinib in non-small cell lung cancer (NSCLC)
    Johnson, F. M.
    Tang, X.
    Tran, H.
    Saigal, B.
    Erasmus, J.
    Kurie, J.
    Hwang, L.
    Oh, Y.
    Lippman, S.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Lim, F.
    Ponce, S.
    Patel, S.
    Van Herpen, C.
    Kurkjian, C.
    Lou, Y.
    Liu, Y.
    Ramsingh, G.
    Pal, S.
    Neal, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S405 - S406
12345